GlassScriptPhysician profile
Seth David Nodine
NPI 1972555993
$12,143.50
in general payments reported to CMS, 2019-2025
46 companies · $2,436 in 2025
The $2,436 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,069 · 2020: $1,001 · 2021: $1,194 · 2022: $1,214 · 2023: $2,122 · 2024: $2,107 · 2025: $2,436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,645 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,645.28 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,694.53 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,390.23 | 2019-2025 | |
| Lilly USA, LLC | $1,190.33 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,178.73 | 2019-2025 | Farxiga, Airsupra, Bevespi Aerosphere |
| Glaxosmithkline, LLC. | $840.58 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $727.36 | 2021-2025 | |
| Amgen INC. | $640.69 | 2019-2025 | Evenity, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $572.25 | 2019-2025 | Spravato, Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $434.65 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $426.06 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $365.53 | 2019-2023 | Belsomra, Steglatro, Lagevrio |
| Teva Pharmaceuticals USA, INC. | $213.71 | 2019-2022 | |
| Astellas Pharma US INC | $203.89 | 2019-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $201.69 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $173.21 | 2024-2025 | Caplyta |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Nodine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.